Results 251 to 260 of about 9,742,950 (352)
Objectives The objectives of this study were to evaluate the correlation and agreement between ultrasound and computed tomography (CT) in measuring ascending aorta diameter in patients with giant cell arteritis (GCA) and to investigate the development of new ascending aortic aneurysms in patients with newly diagnosed GCA. Methods To achieve the primary
Anne C Bull Haaversen +4 more
wiley +1 more source
Establishing a clinical trial site: A primer for aspiring principal investigators. [PDF]
Sramek JJ, Carrillo MS, Cutler NR.
europepmc +1 more source
Introduction There are no Food and Drug Administration (FDA) approved therapies for Raynaud's phenomenon (RP) treatment in the United States (U.S.). Clinical trials have been challenged by study design. Important advances in RP patient reported outcome measures and mechanistic quantification allows RP‐related pain characterization.
Tracy M Frech +4 more
wiley +1 more source
Developing Automatic-Labeled Topic Modeling Based on SAO Structure for Technology Analysis. [PDF]
Park M, Kim S, Yoon B.
europepmc +1 more source
Carry Trades and Currency Crashes
Markus K. Brunnermeier +2 more
semanticscholar +1 more source
Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) in electronic health records (EHRs). Methods We searched MEDLINE, Embase, and CENTRAL databases and included studies that validated case definitions against a reference standard such ...
Constanza Saka‐Herrán +10 more
wiley +1 more source
A bibliometric approach to worldwide scientific production of familial hypophosphataemic rickets in Scopus (2000-2022). [PDF]
Hernández-García F +6 more
europepmc +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source

